ENSYSCE BIOSCIENCE WTS - ENSCW STOCK NEWS

Ensysce Biosciences has announced promising results from clinical trials PF614-102 and PF614-MPAR-101. The PF614-102 study, assessing a novel oxycodone prodrug, confirmed a longer-lasting profile compared to OxyContin, indicating a potential for safer, twice-daily dosing. The PF614-MPAR-101 trial revealed early data on overdose protection capabilities of the combination product. Both studies showed favorable safety profiles, supporting Ensysce's goal of creating safer pain management options. A corporate update call is scheduled for May 17, 2022, to discuss these results further.

Ensysce Biosciences (NASDAQ:ENSC, OTC PINK:ENSCW) announced its participation in two key conferences in May 2022 focusing on opioid research. Dr. William Schmidt will present at the New York Academy of Sciences on May 3, while Dr. Lynn Kirkpatrick, CEO, will discuss critical Multi-Ascending Dose clinical data on May 5 at SMi's Pain Therapeutics Conference in London. The company aims to develop safer, tamper-proof opioids through its proprietary platforms to combat prescription drug abuse and overdose.

Ensysce Biosciences has announced the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022. She succeeds Dr. William Schmidt, who will serve as Senior VP of Clinical Development. Dr. Osman brings over ten years of experience in R&D and medical affairs in the pharmaceutical sector, enhancing the company’s leadership at a critical time. CEO Dr. Lynn Kirkpatrick highlighted Dr. Osman’s expertise in pain management as an asset for upcoming clinical trials focusing on abuse and overdose protection in opioid products.

Ensysce Biosciences reported its Q4 and full-year 2021 results, showing a net loss of $29.1 million, heavily influenced by non-cash expenses of $17.9 million related to convertible notes and warrants. Cash and equivalents increased to $12.3 million from $0.2 million year-over-year. The company successfully financed $15 million to support clinical trials, including the Phase 1 study for PF614-MPAR™, aimed at reducing opioid overdose. Federal grant funding rose to $3.5 million, despite a slight overall decrease compared to 2020. Upcoming BE data is expected to bolster regulatory efforts for PF614.

Ensysce Biosciences (NASDAQ:ENSC) is set to release its fourth quarter and full year 2021 financial results on March 31, 2022. The company specializes in developing safer prescription drugs through innovative technology platforms, focusing on reducing drug abuse and overdose. Following the earnings release, Ensysce will host a corporate update call on April 6, 2022, at 11:00 a.m. ET. This session will offer insights into the company's progress, with a chance for participant Q&A.

Ensysce Biosciences (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company focused on developing safer prescription drugs, announced its participation in the 34th Annual Roth Conference from March 13-15, 2022. CEO Lynn Kirkpatrick and CFO Dave Humphrey will be available for meetings with investors. The company leverages its novel technology platforms, including MPAR™, to create next-generation opioids aimed at reducing overdose risks and supporting those with severe pain. This focus is particularly relevant as drug overdose deaths reach record highs.

Ensysce Biosciences has announced the appointment of Lee Rauch to its board of directors. With nearly 40 years of experience in clinical development and company building, Rauch has previously served as CEO of Viridian Therapeutics and was a founding member of McKinsey & Co.'s International Pharmaceutical Practice. Dr. Bob Gower, Chairman of Ensysce, expressed enthusiasm for her leadership as the company progresses with its pipeline, focusing on safer prescription drugs and innovative opioid solutions to combat abuse and overdose.

Ensysce Biosciences has engaged MZ Group for a strategic investor relations program aimed at enhancing visibility in capital markets. The company focuses on developing safer opioid alternatives through its TAAP and MPAR technology platforms. Ensysce's lead product, PF614, has received FDA Fast-Track Designation, indicating potential for reduced regulatory risk and expedited market entry. The firm aims to address the opioid crisis with innovative drugs that combine abuse deterrence and anti-overdose features, meeting significant market demand.

Ensysce Biosciences announced the results of its special stockholder meeting on January 26, 2022. Key resolutions adopted include the issuance of common stock for convertible notes and warrant exercises, and the approval of the Amended and Restated 2021 Omnibus Incentive Plan. These developments are aimed at advancing Ensysce's efforts in creating safer prescription drugs through its proprietary technology platforms. The company focuses on developing tamper-proof opioids to combat pain and reduce the risk of abuse and overdose.